Skip to main content

Trametinib (GSK1120212) in the treatment of melanoma.

Publication ,  Journal Article
Salama, AKS; Kim, KB
Published in: Expert Opin Pharmacother
April 2013

INTRODUCTION: The discovery of somatic mutations in melanoma has advanced our knowledge of the biology of the disease. The mutations, such as those in NRAS, BRAF, GNAQ and GNA11, promote the growth of melanoma cells in most part through the mitogen-activated protein kinase (MAPK) pathway. Understanding the molecular pathways of some of these mutations has resulted in the successful development of selective BRAF inhibitors. Yet, a cure for advanced melanoma is far from reality. Targeting MAPK/ERK kinase (MEK), an essential intermediary kinase protein within the MAPK pathway, may be a promising way to treat patients with BRAF or other genomic mutation. AREAS COVERED: The authors discuss the MAPK pathway in melanoma and review the preclinical and clinical studies of the MEK inhibitor, trametinib , in melanoma. They also discuss the potential of using trametinib in the targeted therapy of advanced melanoma. EXPERT OPINION: Studies have demonstrated the activity of trametinib in BRAF-mutant melanoma, suggesting that it could be a very reasonable alternative to BRAF inhibitors for these patients. Current clinical investigations have shown great promise with the combination of trametinib and dabrafenib in patients with BRAF-mutant melanoma; a number of clinical trials of trametinib in combination with other targeted drugs are underway.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Expert Opin Pharmacother

DOI

EISSN

1744-7666

Publication Date

April 2013

Volume

14

Issue

5

Start / End Page

619 / 627

Location

England

Related Subject Headings

  • Treatment Outcome
  • Skin Neoplasms
  • Pyrimidinones
  • Pyridones
  • Protein Kinase Inhibitors
  • Pharmacology & Pharmacy
  • Molecular Targeted Therapy
  • Mitogen-Activated Protein Kinase Kinases
  • Melanoma
  • MAP Kinase Signaling System
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Salama, A. K. S., & Kim, K. B. (2013). Trametinib (GSK1120212) in the treatment of melanoma. Expert Opin Pharmacother, 14(5), 619–627. https://doi.org/10.1517/14656566.2013.770475
Salama, April K. S., and Kevin B. Kim. “Trametinib (GSK1120212) in the treatment of melanoma.Expert Opin Pharmacother 14, no. 5 (April 2013): 619–27. https://doi.org/10.1517/14656566.2013.770475.
Salama AKS, Kim KB. Trametinib (GSK1120212) in the treatment of melanoma. Expert Opin Pharmacother. 2013 Apr;14(5):619–27.
Salama, April K. S., and Kevin B. Kim. “Trametinib (GSK1120212) in the treatment of melanoma.Expert Opin Pharmacother, vol. 14, no. 5, Apr. 2013, pp. 619–27. Pubmed, doi:10.1517/14656566.2013.770475.
Salama AKS, Kim KB. Trametinib (GSK1120212) in the treatment of melanoma. Expert Opin Pharmacother. 2013 Apr;14(5):619–627.

Published In

Expert Opin Pharmacother

DOI

EISSN

1744-7666

Publication Date

April 2013

Volume

14

Issue

5

Start / End Page

619 / 627

Location

England

Related Subject Headings

  • Treatment Outcome
  • Skin Neoplasms
  • Pyrimidinones
  • Pyridones
  • Protein Kinase Inhibitors
  • Pharmacology & Pharmacy
  • Molecular Targeted Therapy
  • Mitogen-Activated Protein Kinase Kinases
  • Melanoma
  • MAP Kinase Signaling System